Use of immuno-dominant epitope derived from genotype 4 as a diagnostic reagent for detecting the antibodies against Hepatitis E Virus

Virology Journal

Zhu Cui-xia³  Song Xiao-guo³  Zhang He-qiu³  Wang You-chun²  Wang Guo-hua³  Yang Xi-Qin³  Dai Zhen-hua³  Liu Jing¹  Chen Kun³  He Jing³  Feng Xiao-yan³  Xiu Bing-shui³ 

[1] China National Center For Biotechnology Development, No. 6 West Fourth Ring Road, Beijing, 100036, P.R. China;Department of Cell Biology, National Institute for the Control of Pharmaceutical and Biological Products, No. 2 Tiantanxili, Beijing, 100050, P.R. China;Institute of Basic Medical Sciences, Academy of military Medical Sciences, Taiping Road, Beijing, 100850, P.R. China

关键词: Immunoassay;    Genotype;    ORF3;    ORF2;    HEV;   

Others  :  1150618
DOI  :  10.1186/1743-422X-10-131

 received in 2012-06-29, accepted in 2013-04-18,  发布年份 2013

【 摘 要 】

Background

Despite the genotype 4 has become the dominant cause of hepatitis E disease in China, none antigen derived from genotype 4 of hepatitis E virus (HEV) was used in current commercial anti-HEV immunoassay, and the serological reactivity of antigen derive from genotype 4 is not well-charactered.

Methods

We expressed and purified the 4 main immuno-dominant epitopes derived from genotype 1 and 4 including ORF2 (410-621aa) of genotype 4, ORF3 (47-114aa) of genotype 4, ORF2 (396-606aa) of genotype 1 and ORF3 (56-123aa) of genotype 4.

Results

The ORF2 of genotype 4 displayed good diagnostics performance according to ROC analysis using in-house panel, and the immunoassays based the ORF2 of genotype 4 was then developed to detect the anti-HEV IgG antibodies and evaluated further in 530 anti-HEV IgG positive specimens and 380 negative specimens. The sensitivity and the specificity is 98.1% (520/530) and 94.7% (360/380) for immunoassay based on ORF2 of genotype 4, 96.6% (512/530) and 92.6% (352/380) for commercial immunoassay based on genotype 1. It is noted that all of the positive samples will be detected by combing two assays together. The anti-HEV immunoassays based on genotype 4 are in accordance with Chinese anti-HEV national standard,and show an good agreement of 95.8% with commercial assay (kappa=0.913, P=0.014).

Conclusions

The immunoassay based on ORF2G4 displays good performance, and combining assay based on genotype 1 together with genotype 4 will benefit the HEV diagnosis in large scale samples.

【 授权许可】

   
2013 Bing-shui et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Aye TT, Uchida T, Ma XZ, Lida F, Shikata T, Zhuang H, Win KM: Complete nucleotide sequence of a hepatitis E virus isolated from the Xinjiang epidemic (1986–1988) of China. Nucleic Acids Res 1992, 20:3512-3512.
• [2]Aggarwal R, Naik S: Epidemiology of hepatitis E: current status. J Gastroenterol Hepatol 2009, 24(9):1484-1493.
• [3]Geng J, Wang L, Wang X, Fu H, Bu Q, Liu P, Zhu Y, Wang M, Sui Y, Zhuang H: Potential risk of zoonotic transmission from young swine to human: seroepidemiological and genetic characterization of hepatitis E virus in human and various animals in Beijing. China. J Viral Hepat 2011, 18(10):e583-e590.
• [4]Geng J, Wang L, Wang X, Fu H, Bu Q, Zhu Y, Zhuang H: Study on prevalence and genotype of hepatitis E virus isolated from Rex Rabbits in Beijing, China. J Viral Hepat 2011, 18(9):661-667.
• [5]Reyes GR, Huang CC, Yarbough PO, Tam AW: Hepatitis E virus. Comparison of 'New and Old World' isolates. J Hepatol 1991, 13 Suppl 4:S155-S161.
• [6]Takahashi M, Kusakai S, Mizuo H, Suzuki K, Fujimura K, Masuko K, Sugai Y, Aikawa T, Nishizawa T, Okamoto H: Simultaneous detection of immunoglobulin A (IgA) and IgM antibodies against hepatitis E virus (HEV) Is highly specific for diagnosis of acute HEV infection. J Clin Microbiol 2005, 43(1):49-56.
• [7]Zhang S, Tian D, Zhang Z, Xiong J, Yuan Q, Ge S, Zhang J, Xia N: Clinical significance of anti-HEV IgA in diagnosis of acute genotype 4 hepatitis E virus infection negative for anti-HEV IgM. Dig Dis Sci 2009, 54(11):2512-2518.
• [8]Wu KT, Chung KM, Feng IC, Sheu MJ, Kuo HT, Koay LB, Lin CY, Tang LY, Tsai SL: Acute hepatitis E virus infection in Taiwan 2002–2006 revisited: PCR shows frequent co-infection with multiple hepatitis viruses. J Med Virol 2009, 81(10):1734-1742.
• [9]Aggarwal R, Kini D, Sofat S, Naik SR, Krawczynski K: Duration of viraemia and faecal viral excretion in acute hepatitis E. Lancet 2000, 356(9235):1081-1082.
• [10]Purcell RH, Emerson SU: Hepatitis E: an emerging awareness of an old disease. J Hepatol 2008, 48(3):494-503.
• [11]Schlauder GG, Mushahwar IK: Genetic heterogeneity of hepatitis E virus. J Med Virol 2001, 65(2):282-292.
• [12]Jiménez De Oya N, Galindo I, Gironés O, Duizer E, Escribano JM, Saiz JC: Serological immunoassay for detection of hepatitis E virus on the basis of genotype 3 open reading frame 2 recombinant proteins produced in Trichoplusia ni larvae. J Clin Microbiol 2009, 47(10):3276-3282.
• [13]Zhou YH, Purcell RH, Emerson SU: A truncated ORF2 protein contains the most immunogenic site on ORF2: antibody responses to non-vaccine sequences following challenge of vaccinated and non-vaccinated macaques with hepatitis E virus. Vaccine 2005, 23(24):3157-3165.
• [14]Wang Y, Zhang H, Ling R, Li H, Harrison TJ: The complete sequence of hepatitis E virus genotype 4 reveals an alternative strategy for translation of open reading frames 2 and 3. J Gen Virol 2000, 81(Pt 7):1675-1686.
• [15]Ma H, Song X, Harrison TJ, Zhang H, Huang W, Wang Y: Hepatitis E virus ORF3 antigens derived from genotype 1 and 4 viruses are detected with varying efficiencies by an anti-HEV enzyme immunoassay. J Med Virol 2011, 83(5):827-832.
• [16]Wang Y, Zhang H, Li Z, Gu W, Lan H, Hao W, Ling R, Li H, Harrison TJ: Detection of sporadic cases of hepatitis E virus (HEV) infection in China using immunoassays based on recombinant open reading frame 2 and 3 polypeptides from HEV genotype 4. J Clin Microbiol 2001, 39(12):4370-4379.
• [17]Dong C, Dai X, Shao JS, Hu K, Meng JH: Identification of genetic diversity of hepatitis E virus (HEV) and determination of the seroprevalence of HEV in eastern China. Arch Virol 2007, 152(4):739-746.
• [18]Lam WY, Chan RC, Sung JJ, Chan PK: Genotype distribution and sequence variation of hepatitis E virus, Hong Kong. Emerg Infect Dis 2009, 15(5):792-794.
• [19]Ma H, Song X, Li Z, Harrison TJ, Zhang H, Huang W, Hao W, Kong W, Wang Y: Varying abilities of recombinant polypeptides from different regions of hepatitis E virus ORF2 and ORF3 to detect anti-HEV immunoglobulin M. J Med Virol 2009, 81(6):1052-1061.
• [20]Li F, Zhuang H, Kolivas S, Locarnini SA, Anderson DA: Persistent and transient antibody responses to hepatitis E virus detected by western immunoblot using open reading frame 2 and 3 and glutathione S-transferase fusion proteins. J Clin Microbiol 1994, 32(9):2060-2066.
• [21]Li F, Torresi J, Locarnini SA, Zhuang H, Zhu W, Guo X, Anderson DA: Amino-terminal epitopes are exposed when full-length open reading frame 2 of hepatitis E virus is expressed in Escherichia coli, but carboxy-terminal epitopes are masked. J Med Virol 1997, 52(3):289-300.
• [22]Hu WP, Lu Y, Precioso NA, Chen HY, Howard T, Anderson D, Guan M: Double-antigen enzyme-linked immunosorbent assay for detection of hepatitis E virus-specific antibodies in human or swine sera. Clin Vaccine Immunol 2008, 15(8):1151-1157.
• [23]Zhang H, Dai X, Shan X, Meng J: The Leu477 and Leu613 of ORF2-encoded protein are critical in forming neutralization antigenic epitope of hepatitis E virus genotype 4. Cell Mol Immunol 2008, 5(6):447-456.
• [24]Bendall R, Ellis V, Ijaz S, Ali R, Dalton H: A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. J Med Virol 2010, 82(5):799-805.
• [25]Zhang JZ, Im SW, Lau SH, Chau TN, Lai ST, Ng SP, Peiris M, Tse C, Ng TK, Ng MH: Occurrence of hepatitis E virus IgM, low avidity IgG serum antibodies, and viremia in sporadic cases of non-A, -B, and -C acute hepatitis. J Med Virol 2002, 66(1):40-48.
• [26]Ghabrah TM, Tsarev S, Yarbough PO, Emerson SU, Strickland GT, Purcell RH: Comparison of tests for antibody to hepatitis E virus. J Med Virol 1998, 55(2):134-137.
• [27]Huang S, Zhang X, Jiang H, Yan Q, Ai X, Wang Y, Cai J, Jiang L, Wu T, Wang Z, Guan L, Shih JW, Ng MH, Zhu F, Zhang J, Xia N: Profile of acute infectious markers in sporadic hepatitis E. PLoS One 2010, 5(10):e13560.
• [28]Safe Blood Donation In Safe Blood and Blood products: Identifying low risk donors. WHO Module 2: Anonymous; 2002:pp. 83-pp. 84.
• [29]Khuroo MS, Kamili S, Yattoo GN: Hepatitis E virus infection may be transmitted through blood transfusions in an endemic area. J Gastroenterol Hepatol 2004, 19(7):778-784.